| 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| CDMO业务(元) | 966,951,633.62 | 395,380,617.98 | 1,084,066,450.14 | 468,180,276.34 |
| 肝素钠(原料药)(元) | 1,307,761,166.49 | 698,477,390.14 | 2,673,756,694.95 | 1,610,641,269.75 |
| 肝素钠制剂(元) | 2,979,072,285.05 | 1,547,354,298.06 | 3,210,467,649.36 | 1,601,943,690.81 |
| 其他主营业务(元) | - | - | - | 1,601,943,690.81 |
| 其他(元) | 191,786,974.96 | 71,687,085.89 | 191,119,889.96 | 77,896,903.43 |
| 营业成本(元) | ||||
| CDMO业务(元) | 753,916,479.25 | 323,198,665.66 | 666,732,179.84 | 292,150,033.64 |
| 肝素钠(原料药)(元) | 1,036,999,504.83 | 529,529,023.21 | 1,932,086,333.55 | 1,131,016,349.81 |
| 肝素钠制剂(元) | 1,680,919,628.19 | 845,872,336.34 | 2,076,474,426.26 | 1,052,177,910.89 |
| 其他主营业务(元) | - | - | - | 1,052,177,910.89 |
| 其他(元) | 173,433,136.03 | 58,286,818.06 | 149,716,813.02 | 58,897,847.30 |
| 毛利(元) | ||||
| CDMO业务(元) | 213,035,154.37 | 72,181,952.32 | 417,334,270.30 | 176,030,242.70 |
| 肝素钠(原料药)(元) | 270,761,661.66 | 168,948,366.93 | 741,670,361.40 | 479,624,919.94 |
| 肝素钠制剂(元) | 1,298,152,656.86 | 701,481,961.72 | 1,133,993,223.10 | 549,765,779.92 |
| 其他主营业务(元) | - | - | - | 549,765,779.92 |
| 其他(元) | 18,353,838.93 | 13,400,267.83 | 41,403,076.94 | 18,999,056.13 |
| 毛利率(%) | ||||
| CDMO业务(%) | 22.03 | 18.26 | 38.50 | 37.60 |
| 肝素钠(原料药)(%) | 20.70 | 24.19 | 27.74 | 29.78 |
| 肝素钠制剂(%) | 43.58 | 45.33 | 35.32 | 34.32 |
| 其他主营业务(%) | - | - | - | 34.32 |
| 其他(%) | 9.57 | 18.69 | 21.66 | 24.39 |
| 收入构成(%) | ||||
| CDMO业务(%) | 17.76 | 14.57 | 15.14 | 8.73 |
| 肝素钠(原料药)(%) | 24.02 | 25.75 | 37.35 | 30.05 |
| 肝素钠制剂(%) | 54.71 | 57.04 | 44.84 | 29.88 |
| 其他主营业务(%) | - | - | - | 29.88 |
| 其他(%) | 3.52 | 2.64 | 2.67 | 1.45 |
| 毛利构成(%) | ||||
| CDMO业务(%) | 11.83 | 7.55 | 17.88 | 9.92 |
| 肝素钠(原料药)(%) | 15.04 | 17.67 | 31.77 | 27.03 |
| 肝素钠制剂(%) | 72.11 | 73.38 | 48.58 | 30.99 |
| 其他主营业务(%) | - | - | - | 30.99 |
| 其他(%) | 1.02 | 1.40 | 1.77 | 1.07 |